DiagnaMed’s BRAIN AGE® Brain Health AI Platform Accomplishes Clinical Validation Milestone with Peer-Reviewed Paper
April 25, 2024 08:00 ET
|
DiagnaMed Holdings Corp.
TORONTO, April 25, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI,...
International Consortium Publishes Comprehensive Roadmap for the Clinical Implementation of OGM in Hematological Malignancy Applications
January 03, 2024 08:00 ET
|
Bionano Genomics
Framework was co-authored by an international consortium made up of 18 cancer researchers Publication includes researchers’ recommendations for laboratories planning to adopt optical genome mapping...
Juva Life Brings Bold Outlook for the New Year
January 04, 2021 04:30 ET
|
Juva Life Inc.
VANCOUVER, British Columbia, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a premier California based...
Oncotelic Reports Clinical Validation of Drug Induce Xenogenization (DIX) For Treatment of Glioblastoma and Pancreatic Cancer (PC)
March 04, 2019 09:00 ET
|
Oncotelic Inc
Phase 2 Clinical Data Presented at ASCO-SITC Clinical Immuno-Oncology SymposiumXenogenization through chemotherapy-induced genetic mutations (alkylating agents such as temozolomide) or drug-induced...